Initial Statement of Beneficial Ownership (3)

Date : 11/26/2019 @ 11:42PM
Source : Edgar (US Regulatory)
Stock : Sierra Oncology Inc (SRRA)
Quote : 0.4375  -0.0475 (-9.79%) @ 12:41AM
Sierra Oncology share price Chart
After Hours
Last Trade
Last $ 0.45 ▲ 0.02 (3.77%)

Initial Statement of Beneficial Ownership (3)

FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

ORBIMED ADVISORS LLC
2. Date of Event Requiring Statement (MM/DD/YYYY)
11/22/2019 

3. Issuer Name and Ticker or Trading Symbol

Sierra Oncology, Inc. [SRRA]
(Last)        (First)        (Middle)

601 LEXINGTON AVENUE, 54TH FLOOR
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                          ___X___ 10% Owner
_____ Officer (give title below)        _____ Other (specify below)
(Street)

NEW YORK, NY 10022      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Series A Convertible Preferred Stock  (1)(2) (1)(2)Common Stock 45450000 (1)(2)(3) (1)(2)I See footnote (3)
Series A Warrants  (4)(5) (4)(5)Common Stock 45450000 (3)(4)(5)$.33 I See footnote (3)
Series B Warrants  (6) (6)Common Stock 14998500 (3)(6)$.33 I See footnote (3)
Series A Convertible Preferred Stock  (1)(2) (1)(2)Common Stock 6817500 (1)(2)(7) (1)(2)I See footnote (7)
Series A Warrants  (4)(5) (4)(5)Common Stock 6817500 (4)(5)(7)$.33 I See footnote (7)
Series B Warrants  (6) (6)Common Stock 2249775 (6)(7)$.33 I See footnote (7)
Series A Convertible Preferred Stock  (1)(2) (1)(2)Common Stock 6817500 (1)(2)(8) (1)(2)I See footnote (8)
Series A Warrants  (4)(5) (4)(5)Common Stock 6817500 (4)(5)(8)$.33 I See footnote (8)
Series B Warrants  (6) (6)Common Stock 2249775 (6)(8)$.33 I See footnote (8)

Explanation of Responses:
(1) Each share of Series A Convertible Preferred Stock will automatically convert into 3,030 shares of the Issuer's Common Stock upon the 5th trading date following the Issuer's receiving stockholder approval for the first reverse stock split of the Issuer following November 13, 2019, provided that, the Issuer will not effect any conversion, subject to certain exceptions, if, as a result of such conversion, the holder, together with its affiliates and other attribution parties, would own more than 9.99% of the total number of shares of Common Stock then issued and outstanding, which percentage may be changed to a higher percentage upon 61 days' notice to the Issuer, and provided further that such limitation on exercise will automatically increase to 19.99% of the total number of shares of Common Stock during the period that any employee, manager, partner, managing director or affiliate of such holder is then serving on the Issuer's board of directors.
(2) Mona Ashiya, an employee of OrbiMed Advisors LLC ("OrbiMed Advisors"), is a member of the Issuer's board of directors. The exercise limitation for the Series A Convertible Preferred Stock held by affiliates of OrbiMed Advisors is 19.99%. The Series A Convertible Preferred Stock has no expiration date.
(3) These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP VII") is the general partner of OPI VII and OrbiMed Advisors, a registered investment advisor under the Investment Advisors Act of 1940, as amended, is the managing member of OrbiMed GP VII. By virtue of such relationships, OrbiMed GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein. Each of OrbiMed GP VII, OrbiMed Advisors, Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein disclaims beneficial ownership of the shares held by OPI VII, except to the extent of its or his pecuniary interest therein, if any.
(4) Each Series A Warrant will be exercisable for one share of Common Stock. The Series A Warrants are exercisable on the first trading day following the date the Issuer obtains stockholder approval of an amendment to its certificate of incorporation increasing the aggregate number of authorized shares of its Common Stock, such that the Issuer shall have sufficient authorized but unissued shares of Common Stock, solely for the purpose of enabling the Issuer to issue shares of its Common Stock upon exercise of the Series A Warrants and the Series B Warrants (the "Warrant Exercise Date").
(5) The holder will be prohibited, subject to certain exceptions, from exercising the Series A Warrant for shares of Common Stock if, as a result of such exercise, the holder, together with its affiliates and other attribution parties, would own more than 9.99% of the total number of shares of Common Stock then issued and outstanding, which percentage may be changed at the holder's election to a higher percentage upon 61 days' notice to the Issuer. Each Series A Warrant will expire five years from the date it first becomes exercisable.
(6) Each Series B Warrant will be exercisable for 0.33 shares of Common Stock. The Series B Warrants are exercisable on the Warrant Exercise Date, provided that, at each holder's election, the holder will be prohibited, subject to certain exceptions, from exercising the Series B Warrant for shares of Common Stock if, as a result of such exercise, the holder, together with its affiliates and other attribution parties, would own more than 9.99% of the total number of shares of Common Stock then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer. Each Series B warrant will expire on the 75th day anniversary of the Issuer's announcement of top-line data from MOMENTUM, its planned Phase 3 clinical trial of momelotinib for patients with myelofibrosis.
(7) These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Global Healthcare GP LLC ("Healthcare GP") is the general partner of Genesis and OrbiMed Advisors is the managing member of Healthcare GP. By virtue of such relationships, Healthcare GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by Genesis.
(8) These securities are held of record by OrbiMed Partners Master Fund Limited ("OPM"). OrbiMed Capital LLC ("OrbiMed Capital") is the sole holder of manager shares and sole voting member of OPM. By virtue of such relationships, OrbiMed Capital may be deemed to have voting power and investment power over the securities held by OPM and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Capital exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
ORBIMED ADVISORS LLC
601 LEXINGTON AVENUE
54TH FLOOR
NEW YORK, NY 10022
XX

OrbiMed Capital GP VII LLC
601 LEXINGTON AVENUE
54TH FLOOR
NEW YORK, NY 10022
XX

OrbiMed Global Healthcare GP LLC
601 LEXINGTON AVENUE
54TH FLOOR
NEW YORK, NY 10022
XX

ORBIMED CAPITAL LLC
601 LEXINGTON AVENUE
54TH FLOOR
NEW YORK, NY 10022
XX


Signatures
OrbiMed Advisors LLC; By /s/ Douglas Coon, Chief Compliance Officer11/26/2019
**Signature of Reporting PersonDate

OrbiMed Capital GP VII; By /s/ Douglas Coon, Chief Compliance Officer11/26/2019
**Signature of Reporting PersonDate

OrbiMed Capital LLC; By /s/ Douglas Coon, Chief Compliance Officer11/26/2019
**Signature of Reporting PersonDate

OrbiMed Global Healthcare GP LLC; By /s/ Douglas Coon, Chief Compliance Officer11/26/2019
**Signature of Reporting PersonDate

Sierra Oncology (NASDAQ:SRRA)
Historical Stock Chart

1 Year : From Dec 2018 to Dec 2019

Click Here for more Sierra Oncology Charts.

Sierra Oncology (NASDAQ:SRRA)
Intraday Stock Chart

Today : Monday 9 December 2019

Click Here for more Sierra Oncology Charts.

Latest SRRA Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20191210 01:06:15